IBERDOMIDE (CC-220) IS PHARMACODYNAMICALLY ACTIVE AND HAS DOSE-DEPENDENT IMMUNOSTIMULATORY ACTIVITY IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS IRRESPECTIVE OF PRIOR IMID DRUG TREATMENT: PF559